Supreme Court Rejects Bright-Line Test for Materiality
The Supreme Court unanimously held that companies may have a duty to disclose adverse event reports even if they are not yet statistically significant.
The U.S. Supreme Court unanimously held in Matrixx Initiatives v. Siracusano that statistical significance is not a prerequisite for adverse event reports to be considered "material" in a securities fraud claim. The Court rejected the defendant's proposed bright-line rule, which would have shielded companies from liability for non-disclosure unless there was a statistically significant link between a product and negative effects. Instead, the Court reaffirmed the context-dependent standard from Basic Inc. v. Levinson, focusing on whether a reasonable investor would view the information as having "significantly altered the 'total mix' of information available." For public companies, particularly in the pharmaceutical and medical device industries, this decision means that early-stage safety signals or a small number of troubling reports can be legally material. The ruling involved Zicam, a cold remedy allegedly linked to loss of smell, which accounted for 70% of the company's sales. Counsel should advise clients that materiality is a fact-specific inquiry and that overlooking adverse event reports pending statistical proof poses a substantial litigation risk, especially when making optimistic public statements.